JP2022031784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022031784A5 JP2022031784A5 JP2021190474A JP2021190474A JP2022031784A5 JP 2022031784 A5 JP2022031784 A5 JP 2022031784A5 JP 2021190474 A JP2021190474 A JP 2021190474A JP 2021190474 A JP2021190474 A JP 2021190474A JP 2022031784 A5 JP2022031784 A5 JP 2022031784A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- chimeric antigen
- sequence shown
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000004068 intracellular signaling Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010075254 C-Peptide Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023098770A JP2023116716A (ja) | 2018-04-12 | 2023-06-15 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2025051295A JP2025098166A (ja) | 2018-04-12 | 2025-03-26 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810326346.9A CN110372796B (zh) | 2018-04-12 | 2018-04-12 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| CN201810326346.9 | 2018-04-12 | ||
| PCT/CN2019/081064 WO2019196713A1 (zh) | 2018-04-12 | 2019-04-02 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| JP2020531444A JP7148611B2 (ja) | 2018-04-12 | 2019-04-02 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531444A Division JP7148611B2 (ja) | 2018-04-12 | 2019-04-02 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098770A Division JP2023116716A (ja) | 2018-04-12 | 2023-06-15 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022031784A JP2022031784A (ja) | 2022-02-22 |
| JP2022031784A5 true JP2022031784A5 (cg-RX-API-DMAC7.html) | 2022-09-15 |
| JP7299294B2 JP7299294B2 (ja) | 2023-06-27 |
Family
ID=68162957
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531444A Active JP7148611B2 (ja) | 2018-04-12 | 2019-04-02 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2021190474A Active JP7299294B2 (ja) | 2018-04-12 | 2021-11-24 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2023098770A Pending JP2023116716A (ja) | 2018-04-12 | 2023-06-15 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2025051295A Pending JP2025098166A (ja) | 2018-04-12 | 2025-03-26 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531444A Active JP7148611B2 (ja) | 2018-04-12 | 2019-04-02 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098770A Pending JP2023116716A (ja) | 2018-04-12 | 2023-06-15 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2025051295A Pending JP2025098166A (ja) | 2018-04-12 | 2025-03-26 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11142581B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3778651A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7148611B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200142036A (cg-RX-API-DMAC7.html) |
| CN (3) | CN110372796B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019251016B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3095827A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202009962UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019196713A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110372796B (zh) * | 2018-04-12 | 2023-05-02 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| CN111333732B (zh) * | 2019-12-17 | 2023-02-28 | 中国药科大学 | 一种靶向人bcma且激活nk细胞的双特异性抗体的制备及其应用 |
| KR102371151B1 (ko) * | 2020-03-13 | 2022-03-07 | 주식회사 큐로셀 | 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물 |
| CN112851815B (zh) * | 2020-03-17 | 2023-08-08 | 西安宇繁生物科技有限责任公司 | 抗bcma抗体或其抗原结合片段及其制备方法和应用 |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| CN112251412B (zh) * | 2020-10-12 | 2023-03-28 | 汤朝阳 | 一种靶向bcma的嵌合抗原受体t细胞及其应用 |
| AU2021393434A1 (en) * | 2020-12-02 | 2023-06-22 | Shanghai AbelZeta Ltd. | Bcma-targeted chimeric antigen receptors |
| IL303270A (en) | 2020-12-21 | 2023-07-01 | Allogene Therapeutics Inc | The CD45–GATE vehicle activates a protease |
| CN113173991B (zh) * | 2020-12-31 | 2023-03-28 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
| IL303853A (en) | 2021-01-29 | 2023-08-01 | Allogene Therapeutics Inc | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS |
| US20240059782A1 (en) * | 2022-03-01 | 2024-02-22 | Agilent Technologies, Inc. | Anti-human b cell maturation antigen (bcma) antibodies and their use in immunohistochemistry (ihc) |
| CN119654406A (zh) | 2022-07-29 | 2025-03-18 | 艾洛基治疗公司 | 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞 |
| CN116251188A (zh) * | 2023-01-09 | 2023-06-13 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Stat1抑制剂在制备b细胞淋巴癌放射增敏药物中的应用及该药物 |
| EP4626447A1 (en) * | 2023-03-31 | 2025-10-08 | AbelZeta Inc. | Bispecific chimeric antigen receptors targeting cd20 and bcma |
| CN116444669B (zh) * | 2023-04-04 | 2024-02-13 | 科弈(浙江)药业科技有限公司 | 靶向bcma car-t细胞人源化抗体 |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| CN119119274A (zh) * | 2024-09-26 | 2024-12-13 | 北京昌盛鸿途生物科技有限公司 | 一种靶向bcma的cart细胞及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| WO2012163805A1 (en) | 2011-05-27 | 2012-12-06 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2836239A1 (en) * | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| CA2945620C (en) | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| CA2956002C (en) * | 2014-07-24 | 2023-06-27 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| AU2015360845B2 (en) | 2014-12-12 | 2020-11-26 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| SG11201707089WA (en) | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| EP3368903A1 (en) * | 2015-10-30 | 2018-09-05 | GlaxoSmithKline Intellectual Property Development Limited | Prognostic method |
| EP3436070A4 (en) * | 2016-03-29 | 2019-11-27 | University of Southern California | AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS |
| WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| CA3026778A1 (en) * | 2016-06-07 | 2017-12-14 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| CN107827989A (zh) * | 2017-10-18 | 2018-03-23 | 银丰生物工程集团有限公司 | 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用 |
| CN110372796B (zh) * | 2018-04-12 | 2023-05-02 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
-
2018
- 2018-04-12 CN CN201810326346.9A patent/CN110372796B/zh active Active
- 2018-04-12 CN CN202310450645.4A patent/CN116836297A/zh active Pending
- 2018-04-12 CN CN202310447932.XA patent/CN116514995A/zh active Pending
-
2019
- 2019-04-02 EP EP19784803.9A patent/EP3778651A4/en active Pending
- 2019-04-02 SG SG11202009962UA patent/SG11202009962UA/en unknown
- 2019-04-02 WO PCT/CN2019/081064 patent/WO2019196713A1/zh not_active Ceased
- 2019-04-02 CA CA3095827A patent/CA3095827A1/en active Pending
- 2019-04-02 JP JP2020531444A patent/JP7148611B2/ja active Active
- 2019-04-02 KR KR1020207032269A patent/KR20200142036A/ko not_active Ceased
- 2019-04-02 AU AU2019251016A patent/AU2019251016B2/en active Active
-
2020
- 2020-05-22 US US16/881,668 patent/US11142581B2/en active Active
-
2021
- 2021-09-16 US US17/476,661 patent/US11498973B2/en active Active
- 2021-11-24 JP JP2021190474A patent/JP7299294B2/ja active Active
-
2022
- 2022-09-23 US US17/951,774 patent/US20230053305A1/en active Pending
-
2023
- 2023-06-15 JP JP2023098770A patent/JP2023116716A/ja active Pending
- 2023-06-29 AU AU2023204159A patent/AU2023204159B2/en active Active
-
2025
- 2025-03-26 JP JP2025051295A patent/JP2025098166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022031784A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics | |
| TWI633121B (zh) | 雙特異性活化ｔ細胞之抗原結合分子 | |
| WO2020132574A1 (en) | Protease cleavable bispecific antibodies and uses thereof | |
| JP2018502050A5 (cg-RX-API-DMAC7.html) | ||
| WO2020252907A1 (zh) | 抗cd3e和bcma双特异性抗体及其用途 | |
| WO2022057871A1 (zh) | 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| CN111171155B (zh) | 抗cd3和cd123双特异性抗体及其用途 | |
| CN113272330A (zh) | 一种双特异抗体 | |
| CN114763385A (zh) | 靶向ror1的抗体及其用途 | |
| CN117024592B (zh) | 抗b7h3抗体及其用途 | |
| JP2020530770A5 (cg-RX-API-DMAC7.html) | ||
| US20230355795A1 (en) | Immune antigen specific il-18 immunocytokines and uses thereof | |
| WO2023186077A1 (zh) | 抗pd-1单克隆抗体及其衍生物和用途 | |
| AU2021218069B2 (en) | Anti-HER2 affibody and switchable chimeric antigen receptor using same as switch molecule | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| CA3073331A1 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
| WO2025067496A1 (zh) | 靶向baff-r的全人源抗体、car-t细胞及其应用 | |
| AU2020290962A1 (en) | Immune checkpoint blocking bispecific molecules | |
| WO2023246701A1 (zh) | 一种抗体及其用途 | |
| JP2024513700A (ja) | 抗ワクシニアウイルス抗原抗体並びに関連する組成物及び方法 | |
| CN116063512B (zh) | 多功能重组抗体及其制备方法和应用 | |
| Sun et al. | Discovery of a novel mesothelin specific human antibody VH domain | |
| CN117586408A (zh) | 一种结合tnfr2和b7h3的双特异性抗体 |